- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Synthetic organic
Comment: This compound in an IRAK4 degrader (PROTAC) that is claimed in Kymera Therapeutics' patent WO2022027058A1 . It is intended as a therapeutic for B-cell lymphomas that express oncogenic mutations in MYD88, e.g. the protein variant MYD88L265P. The cereblon binding portion of the molecule is based on the structure of the immunomodulatory imide drug (IMiD) lenalidomide. Compound A simultaneously promotes the degradation of IRAK4 and the zinc-finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), and this mechanism synergistically targets key pro-survival pathways in B-cell lymphomas (MYD88-NFκB and IRF4-Type 1 interferon) to enhance anti-tumour activity.
Kymera have an IRAK4/IMDi degrader (KT-413) in their clinical pipeline, but the name-to-structure has not been disclosed.
|Compound class||Synthetic organic|
|Ligand families/groups||PROTACs, molecular glues and other degraders|
|GtoPdb PubChem SID||461663459|
|Search Google for chemical match using the InChIKey||WDRJGMSUTPVXDH-KBOGUJPVSA-N|
|Search Google for chemicals with the same backbone||WDRJGMSUTPVXDH|
|UniChem Compound Search for chemical match using the InChIKey||WDRJGMSUTPVXDH-KBOGUJPVSA-N|
|UniChem Connectivity Search for chemical match using the InChIKey||WDRJGMSUTPVXDH-KBOGUJPVSA-N|